Kartos Therapeutics Stock
Kartos Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, targeted therapies to improve the lives of cancer patients. Their lead investigational drug, navtemadlin (KRT-232), is a potent and selective oral MDM2 inhibitor designed to reactivate the tumor-suppressing function of p53 by inhibiting the MDM2-p53 interaction.
Sign up for SecondMarket™ to view the market and buy or sell Kartos Therapeutics Stock
Buy + SellSee Kartos Therapeutics Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Kartos Therapeutics Stock Valuation + Share Prices
View real-time Tape D™ data on Kartos Therapeutics stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket™ trading platform.
Get StartedKartos Therapeutics Management Team
Chief Medical Officer
Srdan Verstovsek
Director
Flavia Borellini
Director
Wayne Rothbaum
Director
Roger Ulrich
COO
Beth Mechling
CEO
Jesse McGreivy
Chief Scientific Officer
Todd Covey
Director
David Piacquad
Director
Iain Dukes
Learn More About Kartos Therapeutics Stock
Buy Kartos Therapeutics Stock
01Kartos Therapeutics stock does not trade on public stock exchanges. Kartos Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Kartos Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Sell Kartos Therapeutics Stock
02Kartos Therapeutics Stock does not trade on public stock exchanges. In order to sell Kartos Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Kartos Therapeutics Stock Price
03Kartos Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the Tape D™ database from Nasdaq Private Market, you can view Kartos Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
Kartos Therapeutics Stock Ticker Symbol
04There is no ticker symbol for Kartos Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Criteria to Sell Kartos Therapeutics Stock
05Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Kartos Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Criteria to Buy or Invest in Kartos Therapeutics Stock
06Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Kartos Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Kartos Therapeutics Stock Settlement
07Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Kartos Therapeutics IPO
08Kartos Therapeutics is a private company and has not had an IPO. There is currently no Kartos Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Tape D™ database and gain access to actionable data related to Kartos Therapeutics IPO.
Learn more about Tape D™ private company stock data for institutional investors on the on the Tape D™ Product Page.
Sign up for SecondMarket™ to view the market and buy or sell Kartos Therapeutics Stock
Buy + Sell*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.